What ScreenPoint Medical Reported About the MASAI Transpara Trial

ScreenPoint Medical posted on 30 January 2026 that the final results of the MASAI trial, short for Mammography Screening with Artificial Intelligence, had been published in The Lancet. The company says the trial randomly assigned more than 105,000 women to screening supported by its Transpara software or to standard double reading, and was led by Dr Kristina Lang at Lund University. The figures ScreenPoint reports from the publication are a 12 percent lower rate of interval cancers, meaning cancers found between screening rounds, 27 percent fewer of the more aggressive non-luminal A interval cancers, a 29 percent higher cancer detection rate, 16 percent fewer invasive cancers and 21 percent fewer large T2 or greater cancers in the AI-supported group, sensitivity of 80.5 percent against 73.8 percent, and a 44 percent lower screen-reading workload. Dr Lang is quoted saying earlier detection may make a meaningful difference for women and their health, and chief executive Pieter Kroese is quoted saying that at this level of evidence the question shifts from whether AI should be used to making sure women everywhere benefit. This site's own FDA device records list Transpara clearance K241831, decided on 25 November 2024, to applicant Screenpoint Medical B.V. ScreenPoint's page additionally names 510(k) K232096 and CE marking 0344, which are the company's own statements rather than entries in this site's records.

Why the ScreenPoint Medical MASAI Results Matter to Breast Screening Programs

A randomised trial is a different class of evidence from the retrospective reviews most imaging AI companies publish, because nobody chose which women went into which group. That is why this one is worth reading closely rather than filing with the rest. Two cautions go with it. The trial ran inside a screening program that uses two radiologists on every scan as standard, so the workload saving will not transfer unchanged to a program with one reader, and neither will the comparison. And the interval cancer figure, which is the number that matters most for whether screening is catching disease early enough, is a 12 percent relative reduction, which sounds larger in a headline than it will look in one program's annual counts. The results do not say Transpara will produce the same figures in another population, and a buyer should ask about reader staffing before using these numbers in a business case.

Where the ScreenPoint Medical Update Comes From

ScreenPoint Medical is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

ScreenPoint Medical original source.

How We Would Research the ScreenPoint Medical MASAI Results

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would read the Lancet publication itself rather than the company summary, because the confidence intervals and the absolute numbers behind each percentage are what decide whether the effect is solid.
  2. Then we would check how our own screening program reads mammograms today, since MASAI compared AI support against standard double reading and a single-reader program is not the same baseline.
  3. We would confirm with ScreenPoint which software version the trial used and which clearance covers the version being sold now, because this site's records show seven Transpara clearances between 2018 and August 2026.